Orchid Pharma Limited

NSEI:ORCHPHARMA Stock Report

Market Cap: ₹95.0b

Orchid Pharma Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Manish Dhanuka

Chief executive officer

₹35.5m

Total compensation

CEO salary percentage22.3%
CEO tenure4.6yrs
CEO ownershipn/a
Management average tenure4.6yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

Orchid Pharma Limited's (NSE:ORCHPHARMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Nov 27
Orchid Pharma Limited's (NSE:ORCHPHARMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Earnings Tell The Story For Orchid Pharma Limited (NSE:ORCHPHARMA) As Its Stock Soars 26%

Jul 29
Earnings Tell The Story For Orchid Pharma Limited (NSE:ORCHPHARMA) As Its Stock Soars 26%

We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease

Jun 12
We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease

Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

May 08
Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce

Feb 28
Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce

Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Feb 06
Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump

Dec 18
Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump

CEO Compensation Analysis

How has Manish Dhanuka's remuneration changed compared to Orchid Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹1b

Jun 30 2024n/an/a

₹1b

Mar 31 2024₹36m₹8m

₹922m

Dec 31 2023n/an/a

₹1b

Sep 30 2023n/an/a

₹1b

Jun 30 2023n/an/a

₹775m

Mar 31 2023₹12m₹8m

₹531m

Dec 31 2022n/an/a

-₹175m

Sep 30 2022n/an/a

-₹356m

Jun 30 2022n/an/a

-₹471m

Mar 31 2022₹7m₹7m

-₹604m

Dec 31 2021n/an/a

-₹592m

Sep 30 2021n/an/a

-₹934m

Jun 30 2021n/an/a

-₹1b

Mar 31 2021₹5m₹5m

-₹952m

Compensation vs Market: Manish's total compensation ($USD414.15K) is about average for companies of similar size in the Indian market ($USD351.06K).

Compensation vs Earnings: Manish's compensation has increased by more than 20% in the past year.

CEO

Manish Dhanuka (57 yo)

4.6yrs

Tenure

₹35,510,053

Compensation

Shri. Manish Dhanuka serves as Director at Orchid Pharma Limited since March 31, 2020 and serves as its Managing Director since June 29, 2020. He serves as Non-Executive Non-Independent Director since Nove...

Leadership Team

NamePositionTenureCompensationOwnership
Manish Dhanuka
MD & Director4.6yrs₹35.51mno data
Sunil Gupta
Chief Financial Officer4.6yrs₹5.48mno data
Kapil Dayya
Company Secretary & Compliance Officer1.1yrs₹429.00kno data
Mridul Dhanuka
Whole Time Director4.6yrs₹35.51mno data
Ashok Clifford D
Head of Human Resources24yrsno datano data
Sivaswami Mani
President of APIno data₹6.68mno data
R. Sarangdhar
VP and Unit Head of API & FDFno datano datano data
S. Srinivasan
Head of CTD & IPMno datano datano data
Rajnish Rohatgi
Chief Executive Officer of Orchid AMSless than a yearno datano data
Prabhu Vinayagam
Head of Medico Marke1.2yrsno datano data
Praga Patro
Head of Information Technology17.9yrsno datano data

4.6yrs

Average Tenure

55.5yo

Average Age

Experienced Management: ORCHPHARMA's management team is considered experienced (4.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Manish Dhanuka
MD & Director4.8yrs₹35.51mno data
Mridul Dhanuka
Whole Time Director4.8yrs₹35.51mno data
Ram Agarwal
Non Executive Chairman4.8yrsno datano data
Dharam Vir
Additional Non-Executive & Independent Director4.6yrs₹285.00kno data
Shubha Singh
Additional Independent Non-Executive Directorless than a yearno datano data
Tanu Singla
Additional Non Executive Independent & Woman Director4.6yrs₹245.00kno data
Manoj Goyal
Additional Non Executive & Independent Director4.6yrs₹260.00kno data
Arjun Dhanuka
Additional Non-Executive & Non-Independent Director1.3yrs₹100.00kno data

4.6yrs

Average Tenure

48yo

Average Age

Experienced Board: ORCHPHARMA's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 11:50
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Orchid Pharma Limited is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullAngel Broking Private Limited
Sudarshan PadmanabhanBatlivala & Karani Securities India Pvt. Ltd.
Pauline LauBofA Global Research